Cancer statistics, CA Cancer J Clin, vol.66, issue.1, pp.7-30, 2016. ,
Ductal carcinoma in situ: challenges, opportunities, and uncharted waters, Am Soc Clin Oncol Educ Book, vol.2012, pp.40-44 ,
Current management of lesions associated with an increased risk of breast cancer, Nat Rev Clin Oncol, vol.12, issue.4, pp.227-265, 2015. ,
Ductal carcinoma in situ -update on risk assessment and management, Histopathology, vol.68, issue.1, pp.96-109, 2016. ,
Leveraging premalignant biology for immunebased cancer prevention, Proc Natl Acad Sci, vol.113, issue.39, pp.10750-10758, 2016. ,
Clinical relevance of host immunity in breast cancer: from TILs to the clinic, Nat Rev Clin Oncol, vol.13, issue.4, pp.228-269, 2016. ,
New strategies in breast cancer: immunotherapy, Clin Cancer Res, vol.22, issue.9, pp.2105-2115, 2016. ,
, WHO classification of Tumours of the breast, 2012.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group, Ann Oncol, vol.26, issue.2, pp.259-71, 2014. ,
Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol, vol.11, issue.2, pp.155-68, 1998. ,
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathol Lab Med, vol.138, issue.2, pp.241-56, 2014. ,
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer, Ann Oncol, vol.22, issue.8, pp.1736-1783, 2011. ,
Sem: a suitable statistical software adaptated for research in oncology, Bull Cancer, vol.87, issue.10, pp.715-736, 2000. ,
Angiogenesis and inflammation in ductal carcinoma in situ of the breast, J Pathol, vol.181, issue.2, pp.200-206, 1997. ,
Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations, J Clin Pathol, vol.59, issue.9, pp.972-979, 2006. ,
FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast, Breast Cancer Res Treat, vol.139, issue.2, pp.381-90, 2013. ,
The immune microenvironment of breast ductal carcinoma in situ, Mod Pathol, vol.29, issue.3, pp.249-58, 2016. ,
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast, Breast Cancer Res Treat, 2016. ,
Prognostic significance of in situ carcinoma associated with invasive breast carcinoma. A natural experiment in cancer immunology?, Cancer, vol.78, issue.4, pp.778-88, 1996. ,
The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study, Anticancer Res, vol.22, issue.2B, pp.1231-1239, 2002. ,
Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes, J Clin Pathol, 2016. ,
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis, Cancer Res, vol.71, issue.13, pp.4380-91, 2011. ,
B cells responses and cytokine production are regulated by their immune microenvironment, Cytokine, vol.74, issue.2, pp.318-344, 2015. ,
Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells, Oncogene, vol.28, issue.30, pp.2745-55, 2009. ,
Obesity and inflammation: new insights into breast cancer development and progression, Am Soc Clin Oncol Educ Book, vol.2013, pp.46-51 ,
The immune system and inflammation in breast cancer, Mol Cell Endocrinol, vol.382, issue.1, pp.673-82, 2014. ,
Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer, Cancer Res, vol.61, issue.21, pp.7889-99, 2001. ,
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers, PLoS One, vol.6, issue.3, p.17876, 2011. ,
NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer, PLoS One, vol.7, issue.6, p.38783, 2012. ,
MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelialmesenchymal transition, Neoplasma, vol.63, issue.1, pp.44-56, 2016. ,
The genomic landscape of breast cancer and its interaction with host immunity, Breast, vol.29, pp.241-50, 2016. ,
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells, Nat Immunol, vol.4, issue.4, pp.330-336, 2003. ,
T-regulatory cells: key players in tumor immune escape and angiogenesis, Cancer Res, vol.72, issue.9, pp.2162-71, 2012. ,
New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape, Curr Opin Immunol, vol.27, pp.16-25, 2014. ,
Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases, Pathol Int, vol.53, issue.7, pp.422-430, 2003. ,
Pathological assessment of microinvasive carcinoma of the breast, Breast Cancer, vol.20, issue.4, pp.331-336, 2013. ,
Mammary ductal carcinoma in situ with microinvasion, Cancer, vol.82, issue.12, pp.2382-90, 1998. ,
Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy, Ann Surg Oncol, vol.20, issue.3, pp.811-819, 2013. ,
Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast, Tumour Biol, vol.36, issue.4, pp.2241-2249, 2015. ,
Microinvasive ductal carcinoma of the breast treated with breastconserving surgery and definitive irradiation, Int J Radiat Oncol Biol Phys, vol.23, issue.5, pp.961-969, 1992. ,
Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas, Cancer, vol.94, issue.8, pp.2134-2176, 2002. ,
Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report, BMC Res Notes, vol.7, p.325, 2014. ,